These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 17300492)

  • 1. Improved long-term graft function in kidney transplant recipients with donor antigen-specific hyporeactivity.
    Ferraris J; Tambutti M; Prigoshin N
    Pediatr Transplant; 2007 Mar; 11(2):139-44. PubMed ID: 17300492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence that improved late renal transplant outcome correlates with the development of in vitro donor antigen-specific hyporeactivity.
    Reinsmoen NL; Matas AJ
    Transplantation; 1993 May; 55(5):1017-23. PubMed ID: 7684534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term evaluation of proliferative donor antigen-specific reactivity in cadaveric kidney transplant recipients.
    Böhmig GA; Säemann MD; Bergmann M; Watschinger B; Regele H; Windhager T; Mühlbacher F; Hörl WH; Zlabinger GJ
    Transpl Int; 2000; 13(3):187-93. PubMed ID: 10935701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
    Ciancio G; Miller A; Burke GW; Gharagozloo H; Rosen A; Roth D; Kupin W; Pinna A; Cespedes M; Esquenazi V; Miller J
    Transplant Proc; 2001; 33(1-2):1013-4. PubMed ID: 11267169
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.
    Kandus A; Grego K; Bren AF
    Ther Apher Dial; 2005 Jun; 9(3):262-4. PubMed ID: 15967003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
    Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of daclizumab, tacrolimus, and mycophenolate mofetil in pediatric first renal transplant recipients.
    Ciancio G; Burke GW; Suzart K; Mattiazzi A; Rosen A; Zilleruello G; Abitbol C; Montane B; Miller J
    Transplant Proc; 2002 Aug; 34(5):1944-5. PubMed ID: 12176637
    [No Abstract]   [Full Text] [Related]  

  • 8. Improved long-term graft outcome in lung transplant recipients who have donor antigen-specific hyporeactivity.
    Reinsmoen NL; Bolman RM; Savik K; Butters K; Matas AJ; Hertz MI
    J Heart Lung Transplant; 1994; 13(1 Pt 1):30-6; discussion 36-7. PubMed ID: 7513186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of daclizumab to reduce delayed graft function in non-heart-beating renal transplantation: a prospective, randomized trial.
    Wilson C; Brook NR; Gok MA; Gupta A; Asher JF; Nicholson ML; Talbot D
    Transplant Proc; 2005 May; 37(4):1774-5. PubMed ID: 15919462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
    Sarwal MM; Vidhun JR; Alexander SR; Satterwhite T; Millan M; Salvatierra O
    Transplantation; 2003 Nov; 76(9):1331-9. PubMed ID: 14627912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
    Grego K; Arnol M; Bren AF; Kmetec A; Tomaziĉ J; Kandus A
    Transplant Proc; 2007 Dec; 39(10):3093-7. PubMed ID: 18089329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of calcineurin inhibitors (CNIs) and steroid avoidance immunosuppressive protocol among living donor kidney transplant recipients.
    Oh HK; Ding P; Satmary NA
    Yonsei Med J; 2004 Dec; 45(6):1143-8. PubMed ID: 15627310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daclizumab to prevent rejection after cardiac transplantation.
    Hershberger RE; Starling RC; Eisen HJ; Bergh CH; Kormos RL; Love RB; Van Bakel A; Gordon RD; Popat R; Cockey L; Mamelok RD
    N Engl J Med; 2005 Jun; 352(26):2705-13. PubMed ID: 15987919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Campath-1H in renal transplantation: The University of Wisconsin experience.
    Knechtle SJ; Fernandez LA; Pirsch JD; Becker BN; Chin LT; Becker YT; Odorico JS; D'alessandro AM; Sollinger HW
    Surgery; 2004 Oct; 136(4):754-60. PubMed ID: 15467659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
    Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients.
    Kovac D; Kotnik V; Kandus A
    Transplant Proc; 2005 Dec; 37(10):4230-4. PubMed ID: 16387086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organ-specific patterns of donor antigen-specific hyporeactivity and peripheral blood allogeneic microchimerism in lung, kidney, and liver transplant recipients.
    Reinsmoen NL; Jackson A; McSherry C; Ninova D; Wiesner RH; Kondo M; Krom RA; Hertz MI; Bolman RM; Matas AJ
    Transplantation; 1995 Dec; 60(12):1546-54. PubMed ID: 8545888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol.
    Schachter AD; Meyers KE; Spaneas LD; Palmer JA; Salmanullah M; Baluarte J; Brayman KL; Harmon WE
    Pediatr Transplant; 2004 Apr; 8(2):171-7. PubMed ID: 15049798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.